Information Provided By: 
Fly News Breaks for April 27, 2017
ALKS
Apr 27, 2017 | 11:40 EDT
Leerink analyst Paul Matteis describes Alkermes' Q1 as "tough" with earnings and revenue missing expectations. The miss was driven by lower than expected Vivitrol and Aristada revenues, as well as higher spending, Matteis tells investors in a post-earnings research note. The analyst notes that he only made "modest tweaks" to his forward projections and that his Vivitrol thesis is intact. Matteis keeps an Outperform rating on Alkermes with a $68 price target. The stock in late morning trading is down $1.63 to $55.50.
News For ALKS From the Last 2 Days
